Nuvalent Inc (NUVL) Files for up to $100M IPO

Nuvalent Inc (NASDAQ: NUVL) files for up to $100M IPO.

The company describes itself as: "We are a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, we focus on “clinically proven” kinase targets, or those for which therapies have been developed by others to target those kinases, and that such drugs have demonstrated sufficient clinical efficacy and safety data to be approved by the United States Food and Drug Administration, or FDA, or similar regulatory agency and are established and used in the clinical setting. We leverage our team’s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed to overcome the limitations of those existing therapies."

J.P. Morgan, Cowen and Piper Sandler will serve as underwriters.

You May Also Be Interested In

• Braveheart Bio raises $439.9M in upsized Nasdaq IPO
• Braveheart Bio prices IPO at $18 per share, raises $382.5M
• TD Cowen Starts Obsidian Therapeutics (OBX) at Buy